聚化合物对过敏性鼻炎的临床影响:系统审查和元分析
Yun-Ru Lai1, Yi-Hsueh Liao2, Li Huang1
1Department of Family Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
多化合物在减少过敏性鼻炎 (AR) 的打喷和等鼻过敏症状方面表现有前途. 然而,证据质量较低,需要进一步研究才能得出最终结论.
科学领域:
- 免疫学和过敏学
- 营养科学 营养科学
- 基于证据的医学基于证据的医学.
背景情况:
- 聚化合物,包括甲基素和氨酸,正在研究它们对减轻过敏和过敏症的潜力.
- 关于多对过敏症状的疗效的现有临床证据是不一致的,强调需要进一步评估.
研究的目的:
- 系统地评估聚化合物在治疗过敏性鼻炎 (AR) 中的治疗潜力.
- 综合来自随机对照试验 (RCT) 关于多对AR症状和生活质量 (QoL) 的影响的证据.
主要方法:
- 一项对13项随机对照试验 (RCT) 的系统审查和元分析,涉及823名患有季节性和长期过敏性鼻炎的参与者.
- 使用标准化平均差异 (SMD) 的统计分析来评估多化合物对各种AR症状和QOL的影响.
主要成果:
- 多化合物显著降低了季节性AR的总鼻腔症状得分,打喷和鼻.
- 在长期AR中,总鼻腔症状得分有所改善,但个体症状数据是不确定的.
- 综合分析证实,鼻腔症状总得分,鼻腔阻塞和打喷显著减少,尽管证据的整体确定性低至非常低.
结论:
- 多化合物可能提供一种补充方法来缓解过敏性鼻炎中的鼻腔症状.
- 由于证据的确定性低到非常低,目前的调查结果应谨慎解释.
- 需要更大规模,高质量的RCT来确定最终的疗效和安全性.
更多相关视频
03:40Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
06:34A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
Published on: June 4, 2017
相关概念视频
Allergic Reactions
Allergic Drug Reactions
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
